Artios doses first patient in Phase 2 POLKA study
The trial evaluates Pol-theta inhibitor ART6043 plus olaparib versus olaparib alone in gBRCA-mutated HER2-negative breast cancer, following FDA Fast Track designation.
See the latest news and media coverage for Artios. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage oncology drug development company
artios.comLast updated
In short: Artios dosed the first patient in its Phase 2 POLKA trial of ART6043 plus olaparib.
The trial evaluates Pol-theta inhibitor ART6043 plus olaparib versus olaparib alone in gBRCA-mutated HER2-negative breast cancer, following FDA Fast Track designation.
Low dose alnodesertib plus gemcitabine improved progression-free survival in platinum-resistant high-grade serous ovarian cancer, with a 29% reduction in risk of progression or death versus gemcitabine alone.
Proceeds fund Phase 2 trials of alnodesertib in pancreatic and colorectal cancer and ART6043 in breast cancer, plus a DDRi-ADC lead candidate.
ART6043 showed a benign tolerability profile and promising clinical signals with olaparib in advanced solid tumors, supporting advancement into Phase 2 development.
ART0380 in combination with low-dose irinotecan demonstrated a 50% confirmed overall response rate (cORR) in patients with Ataxia-Telangiectasia Mutated (ATM)-negative1 solid tumors at the recommended...
LONDON, 27 July 2021: Arix Bioscience plc ("Arix", LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, today...
Novartis is partnering with Artios Pharma to develop cancer therapies that couple Artios's synthetic lethality technology with Novartis's radioligands. Artios will get $20 million to...
LONDON - DNA damage repair (DDR) specialist Artios Pharma Ltd. has sealed a $860 million per target deal with Merck KGaA, around a series of...
Track Artios and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Artios and other trending companies.